Galderma的新型透明质酸填充剂Rystylane Kysse,获得FDA批准用于丰唇

2020-05-06 MedSci原创 MedSci原创

“Restylane Kysse的批准能够为患者的嘴唇提供自然的外观效果,尤其是当他们说话、微笑甚至亲吻时,这些效果就更加显着。"

Galderma公司宣布,美国食品和药物管理局(FDA)已批准Restylane Kysse用于21岁以上成年人的丰唇和抚平上唇皱纹。Restylane Kysse作为一种透明质酸(HA)填充剂,被证明在给药后药效可以持续长达1年,患者的满意度很高。

该公司副总裁Alisa Lask表示:" Restylane Kysse是一种新型的唇填充剂,可通过唇部注射达到令人满意的疗效。我们有信心Restylane Kysse有可能成为美国市场上领先的唇填充剂。"

与支持批准的第3阶段试验中的对比剂(2.24 mL)相比,Restylane Kysse仅需要较少量(1.82 mL)的注射就能显示出自然的嘴唇丰度。Restylane Kysse被证明是安全且耐受良好,它包含利多卡因,一种用于局部麻木的药物,以减轻疼痛和注射相关的不适感。

加利福尼亚圣地亚哥的皮肤科医生和美容外科医师Melanie Palm博士说:"Resylane Kysse的配方改变了游戏规则,为双唇带来出色的效果。这项新的批准使我能够为患者的嘴唇提供自然的外观效果,尤其是当他们说话、微笑甚至亲吻时,这些效果就更加显着。"

原始出处:

https://www.firstwordpharma.com/node/1721553?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1839809, encodeId=792418398098e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Mar 17 16:59:48 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276735, encodeId=86b812e673580, content=<a href='/topic/show?id=ec9e9482383' target=_blank style='color:#2F92EE;'>#透明质酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94823, encryptionId=ec9e9482383, topicName=透明质酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469420, encodeId=84001469420f5, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587549, encodeId=e446158e54905, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593893, encodeId=2ed2159389382, content=<a href='/topic/show?id=01b15829615' target=_blank style='color:#2F92EE;'>#新型透明质酸填充剂Rystylane Kysse#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58296, encryptionId=01b15829615, topicName=新型透明质酸填充剂Rystylane Kysse)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04f818178383, createdName=zhangmingxiang, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2021-03-17 bugit
  2. [GetPortalCommentsPageByObjectIdResponse(id=1839809, encodeId=792418398098e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Mar 17 16:59:48 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276735, encodeId=86b812e673580, content=<a href='/topic/show?id=ec9e9482383' target=_blank style='color:#2F92EE;'>#透明质酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94823, encryptionId=ec9e9482383, topicName=透明质酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469420, encodeId=84001469420f5, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587549, encodeId=e446158e54905, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593893, encodeId=2ed2159389382, content=<a href='/topic/show?id=01b15829615' target=_blank style='color:#2F92EE;'>#新型透明质酸填充剂Rystylane Kysse#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58296, encryptionId=01b15829615, topicName=新型透明质酸填充剂Rystylane Kysse)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04f818178383, createdName=zhangmingxiang, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1839809, encodeId=792418398098e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Mar 17 16:59:48 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276735, encodeId=86b812e673580, content=<a href='/topic/show?id=ec9e9482383' target=_blank style='color:#2F92EE;'>#透明质酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94823, encryptionId=ec9e9482383, topicName=透明质酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469420, encodeId=84001469420f5, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587549, encodeId=e446158e54905, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593893, encodeId=2ed2159389382, content=<a href='/topic/show?id=01b15829615' target=_blank style='color:#2F92EE;'>#新型透明质酸填充剂Rystylane Kysse#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58296, encryptionId=01b15829615, topicName=新型透明质酸填充剂Rystylane Kysse)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04f818178383, createdName=zhangmingxiang, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-05-08 zhangjingnwpu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1839809, encodeId=792418398098e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Mar 17 16:59:48 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276735, encodeId=86b812e673580, content=<a href='/topic/show?id=ec9e9482383' target=_blank style='color:#2F92EE;'>#透明质酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94823, encryptionId=ec9e9482383, topicName=透明质酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469420, encodeId=84001469420f5, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587549, encodeId=e446158e54905, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593893, encodeId=2ed2159389382, content=<a href='/topic/show?id=01b15829615' target=_blank style='color:#2F92EE;'>#新型透明质酸填充剂Rystylane Kysse#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58296, encryptionId=01b15829615, topicName=新型透明质酸填充剂Rystylane Kysse)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04f818178383, createdName=zhangmingxiang, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-05-08 xuqianhua
  5. [GetPortalCommentsPageByObjectIdResponse(id=1839809, encodeId=792418398098e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Mar 17 16:59:48 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276735, encodeId=86b812e673580, content=<a href='/topic/show?id=ec9e9482383' target=_blank style='color:#2F92EE;'>#透明质酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94823, encryptionId=ec9e9482383, topicName=透明质酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469420, encodeId=84001469420f5, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587549, encodeId=e446158e54905, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593893, encodeId=2ed2159389382, content=<a href='/topic/show?id=01b15829615' target=_blank style='color:#2F92EE;'>#新型透明质酸填充剂Rystylane Kysse#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58296, encryptionId=01b15829615, topicName=新型透明质酸填充剂Rystylane Kysse)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04f818178383, createdName=zhangmingxiang, createdTime=Fri May 08 07:59:48 CST 2020, time=2020-05-08, status=1, ipAttribution=)]

相关资讯

FDA批准艾尔健自然丰唇产品JUVÉDERM VOLBELLA® XC

全球医疗美容行业的领导者艾尔建(Allergan)近日宣布,美国食品和药物管理局(FDA)已批准该公司丰唇产品JUVÉDERM VOLBELLA® XC,用于21岁以上成人群体,用于丰唇及矫正口周皱纹(perioral rhytids,俗称“口周纹”)。在临床试验中,JUVÉDERM VOLBELLA® XC被发现能够有效的、持久的增加嘴唇丰满度,同时可柔化口周纹路。JUVÉDERM VOLBEL

美容业重磅消息!FDA批准艾尔健自然丰唇产品JUVÉDERM VOLBELLA® XC

全球医疗美容行业的领导者艾尔建(Allergan)近日宣布,美国食品和药物管理局(FDA)已批准该公司丰唇产品JUVÉDERM VOLBELLA® XC,用于21岁以上成人群体,用于丰唇及矫正口周皱纹(perioral rhytids,俗称“口周纹”)。在临床试验中,JUVÉDERM VOLBELLA® XC被发现能够有效的、持久的增加嘴唇丰满度,同时可柔化口周纹路。JUVÉDERM VOLBEL